Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Reply to: Lack of Diagnostic Utility of "Amino Acid Dysregulation Metabotypes".

Smith AM, Donley ELR, Burrier RE, King JJ, Amaral DG.

Biol Psychiatry. 2018 Dec 27. pii: S0006-3223(18)32025-0. doi: 10.1016/j.biopsych.2018.11.013. [Epub ahead of print] No abstract available.

PMID:
30595230
2.

Amino Acid Dysregulation Metabotypes: Potential Biomarkers for Diagnosis and Individualized Treatment for Subtypes of Autism Spectrum Disorder.

Smith AM, King JJ, West PR, Ludwig MA, Donley ELR, Burrier RE, Amaral DG.

Biol Psychiatry. 2019 Feb 15;85(4):345-354. doi: 10.1016/j.biopsych.2018.08.016. Epub 2018 Sep 6.

3.

Biocon's target factory.

Neenan TX, Burrier RE, Kim S.

Nat Biotechnol. 2018 Sep 6;36(9):791-797. doi: 10.1038/nbt.4242. No abstract available.

PMID:
30188545
4.

A human induced pluripotent stem cell-based in vitro assay predicts developmental toxicity through a retinoic acid receptor-mediated pathway for a series of related retinoid analogues.

Palmer JA, Smith AM, Egnash LA, Colwell MR, Donley ELR, Kirchner FR, Burrier RE.

Reprod Toxicol. 2017 Oct;73:350-361. doi: 10.1016/j.reprotox.2017.07.011. Epub 2017 Jul 23.

PMID:
28746836
5.

Metabolomics as a tool for discovery of biomarkers of autism spectrum disorder in the blood plasma of children.

West PR, Amaral DG, Bais P, Smith AM, Egnash LA, Ross ME, Palmer JA, Fontaine BR, Conard KR, Corbett BA, Cezar GG, Donley EL, Burrier RE.

PLoS One. 2014 Nov 7;9(11):e112445. doi: 10.1371/journal.pone.0112445. eCollection 2014.

6.

Establishment and assessment of a new human embryonic stem cell-based biomarker assay for developmental toxicity screening.

Palmer JA, Smith AM, Egnash LA, Conard KR, West PR, Burrier RE, Donley EL, Kirchner FR.

Birth Defects Res B Dev Reprod Toxicol. 2013 Aug;98(4):343-63. doi: 10.1002/bdrb.21078. Epub 2013 Oct 3.

PMID:
24123775
7.

The sodium-dependent ascorbic acid transporter family SLC23.

Bürzle M, Suzuki Y, Ackermann D, Miyazaki H, Maeda N, Clémençon B, Burrier R, Hediger MA.

Mol Aspects Med. 2013 Apr-Jun;34(2-3):436-54. doi: 10.1016/j.mam.2012.12.002. Review.

PMID:
23506882
8.

The ABCs of membrane transporters in health and disease (SLC series): introduction.

Hediger MA, Clémençon B, Burrier RE, Bruford EA.

Mol Aspects Med. 2013 Apr-Jun;34(2-3):95-107. doi: 10.1016/j.mam.2012.12.009. Review.

9.

A roadmap for the development of alternative (non-animal) methods for systemic toxicity testing.

Basketter DA, Clewell H, Kimber I, Rossi A, Blaauboer B, Burrier R, Daneshian M, Eskes C, Goldberg A, Hasiwa N, Hoffmann S, Jaworska J, Knudsen TB, Landsiedel R, Leist M, Locke P, Maxwell G, McKim J, McVey EA, Ouédraogo G, Patlewicz G, Pelkonen O, Roggen E, Rovida C, Ruhdel I, Schwarz M, Schepky A, Schoeters G, Skinner N, Trentz K, Turner M, Vanparys P, Yager J, Zurlo J, Hartung T.

ALTEX. 2012;29(1):3-91. doi: 10.14573/altex.2012.1.003.

PMID:
22307314
10.

Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function.

Rouleau C, Roy A, St Martin T, Dufault MR, Boutin P, Liu D, Zhang M, Puorro-Radzwill K, Rulli L, Reczek D, Bagley R, Byrne A, Weber W, Roberts B, Klinger K, Brondyk W, Nacht M, Madden S, Burrier R, Shankara S, Teicher BA.

Mol Cancer Ther. 2006 Feb;5(2):219-29.

11.

Toxin binding of tolevamer, a polyanionic drug that protects against antibiotic-associated diarrhea.

Braunlin W, Xu Q, Hook P, Fitzpatrick R, Klinger JD, Burrier R, Kurtz CB.

Biophys J. 2004 Jul;87(1):534-9.

Supplemental Content

Loading ...
Support Center